ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Trial Profile

ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs Nivolumab (Primary) ; Capecitabine; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 28 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Aug 2020.
    • 24 Feb 2017 Planned number of patients changed from 268 to 680.
    • 24 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top